Does Dose Intensification of ONC201 Promote an Immune Response?


  • ONC201 is a novel small molecule which is in clinical trials for both solid and hematopoietic malignancies. To further evaluate its mechanism of action, preclinical studies were developed to determine if increases in dose would not only impact antitumor efficacy and inhibit metastasis, but also promote an intra-tumoral immune response. View this webinar and learn how Drs. Jessica Wagner from St. Jude’s Children’s Research Hospital and Dr. Harvey Hensley from Fox Chase Cancer Center investigated this hypothesis using various techniques including in vivo imaging to track tumor growth and microscopy imaging of IHC xenograft tissue sections to elucidate the immune-stimulatory and anti-metastatic potency of ONC201.